- American City Business Journals•4 hours ago
EyeGate Pharmaceuticals, an 11-employee biotech headquartered in Waltham, saw its market cap more than double on Tuesday after announcing a licensing deal with Valeant Pharmaceuticals that could be worth up to $103 million. Under the deal, EyeGate received a $4 million upfront payment. As of 3 p.m. Tuesday afternoon, shares of EyeGate had increased by nearly 130 percent, boosting the company’s market cap from $15.7 million to almost $36 million.
- TheStreet.com•5 hours ago
The company paid $4 million up front for the licensing rights for Eyegate's drop device.
- 24/7 Wall St.•10 hours ago
A few biopharma companies have made massive runs on Tuesday morning.
VRX : Summary for Valeant Pharmaceuticals Interna - Yahoo Finance
Valeant Pharmaceuticals International, Inc. (VRX)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||16.13 - 16.47|
|52 Week Range||13.00 - 86.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.50|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|